-
Tottenham sign Italy's Tonali from Newcastle
-
Stock markets diverge as tech recovery stutters
-
Jolted by Ebola, countries try again to finish pandemic treaty
-
Springboks recall Papier and make 10 changes for Scotland Test
-
Fashion forward: Osaka targets Wimbledon glory
-
Indonesia, Singapore say key oil passage will remain 'accessible'
-
FIFA have 'crossed a red line' in Balogun reprieve: UEFA
-
USA face Belgium and World Cup date with destiny after Trump intervention
-
Fears new pan-European company status threatens workers' rights
-
Oldest quasars ever discovered add to 'perplexing' space mystery
-
'Our game, not theirs': Klopp slams FIFA's Balogun decision
-
German factory orders unexpectedly rebound in May
-
Damage but no casualties reported from Pacific super typhoon
-
Russian strike kills 14 around Kyiv on eve of NATO summit
-
Sky strengthens UK streaming offer with ITV deal
-
USA face Belgium and World Cup date with destiny after Balogun reprieve
-
Experts urge caution as demand grows for AC in heatwave-hit UK
-
Immobilised by heatwave, handicapped man sues Austria in rights court
-
Thousands flee raging wildfires in southern Europe
-
Bellingham tells England to believe after Mexico masterclass
-
Tuchel hails 'heroic' England win in Mexico, but joy soured by Henderson injury
-
'Major' damage as super typhoon hits US islands
-
Bellingham savours 'best night of England career' after Mexico heroics
-
Kane says England found a way to win
-
Ancelotti fails in mission to end Brazil's World Cup woe
-
England, Norway advance at World Cup, FIFA ruling triggers uproar
-
Bellingham powers 10-man England past Mexico, into World Cup quarters
-
Asian markets mixed as tech recovery stutters, oil slips
-
Canada's McIntosh breaks 200 fly world record, oldest in women's swimming
-
Russia launches deadly barrage on Kyiv region on eve of NATO summit
-
Norway dance to Haaland's beat in 'surreal' World Cup run
-
'Major' damage as Super Typhoon Bavi hits US island of Rota
-
Daddy issues? NATO's Rutte sticks to charm to keep Trump on side
-
Australia signs defence alliance with Pacific nation Fiji
-
Norway's World Cup win over Brazil beyond my dreams, says Haaland
-
Philippine Senate trial to decide VP Duterte's political future
-
Neymar calls time on Brazil career after World Cup elimination
-
Australia PM apologises for Kylie Minogue comments
-
Ancelotti promises Brazil will bounce back after World Cup exit
-
Helio Files New Patent Family Covering Precision Deployable Boom Technology, Expanding Intellectual Property
-
Ryde Signs MOU with UISEE to Explore Strategic Collaboration in Autonomous Vehicle Projects in Singapore
-
What Is BTC Worth? New Pricing Model May be Key to Reveal the Answer
-
Vanta to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22, 2026, at 10:00 a.m. ET
-
Banyan Gold Expands High-Grade Domains at Powerline, AurMac Project, Yukon, Canada
-
What is the Best Social Media Platform for Plastic Surgeons?
-
Grande Portage Resources Reports Positive Results from Preliminary Strength Testing of Mine Backfill Materials
-
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - July 06
-
Penalty save inspired Norway, says 'keeper Nyland
-
Mexico-England World Cup match delayed one hour due to storms
US Supreme Court to weigh in on abortion pill access
The US Supreme Court was poised to wade into the divisive battle over the abortion drug mifepristone with a ruling due Friday on lower court-ordered restrictions on the widely used pill.
The nation's highest court has until midnight Eastern Time Friday (0400 GMT Saturday) to decide how it will handle the most significant abortion case since it tossed out the constitutional right to the procedure last year.
The conservative-dominated bench had been scheduled to issue a ruling by Wednesday -- but it extended a stay freezing the lower court decisions for two days as it decides what to do next.
The court can rule in any number of ways, and abortion rights and anti-abortion activists -- as well as millions of Americans -- are on tenterhooks waiting to seehow it proceeds.
The case stems from a ruling by a US District Court judge in Texas that would have banned mifepristone, which was approved by the Food and Drug Administration in 2000 and accounts for more than half of all abortions in the United States.
An appeals court blocked a ban on the pill, but imposed tough restrictions on access, after which the baton was handed to the Supreme Court, where conservatives wield a 6-3 majority.
The Supreme Court could further freeze the lower court rulings pending an appeal from the Justice Department and mifepristone manufacturer Danco Laboratories.
It could also allow the rulings restricting access to the abortion pill to take effect while the appeals play out.
The court could also decide to hear arguments in the case itself on an expedited basis.
Complicating the case even further is a ruling by a separate federal court in Washington state that said access to mifepristone should be maintained.
Since the Supreme Court overturned the landmark Roe v. Wade ruling that enshrined the constitutional right to abortion for half a century, 13 states have banned abortion and it has been severely restricted in others.
- 'Deeply misguided' -
Opposition to the legal assault on the abortion pill is being spearheaded by the Justice Department, which argued that the initial federal judge's ruling was based on a "deeply misguided assessment" of the pill's safety.
Mifepristone is one component of a two-drug regimen that can be used through the first 10 weeks of pregnancy.
It has a long safety record, and the FDA estimates 5.6 million Americans have used it to terminate pregnancies since it was approved.
The appellate court, while striking down the ban on mifepristone, restricted its use to seven weeks of pregnancy, down from 10, and prohibited distribution by mail.
In a filing to the court on Tuesday, the anti-abortion coalition that first brought the case against the FDA repeated their controversial claims that the drug was unsafe.
The coalition said the FDA and distributor of mifepristone had "brazenly flouted the law and applicable regulations ... and continually placed politics above women's health."
Polls repeatedly show a clear majority of Americans support continued access to safe abortion, even as conservative groups push to limit the procedure -- or ban it outright.
H.Romero--AT